ישראל - עברית - Ministry of Health

תמר שיווק מוצרי בריאות טבעיים בעמ - ליפ גלוס

ישראל - עברית - Ministry of Health

sanofi israel ltd - metronidazole as benzoate - תרחיף - metronidazole as benzoate 25 mg/ml - metronidazole - metronidazole - infections caused by anaerobic bacterias, amebiosis, lambliasis and trichomonas.

ישראל - עברית - Ministry of Health

אבון קוסמטיקה ישראל בעמ - הזנה לפנים

ישראל - עברית - Ministry of Health

שמעון שסטוביץ בעמ - שיפור מראה העור

ישראל - עברית - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

ישראל - עברית - Ministry of Health

bayer israel ltd - moxifloxacin - תמיסה לאינפוזיה - moxifloxacin 400 mg / 250 ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.